Vincristine Sulfate
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00541 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | ganglioneuroblastoma (disease) | KG + DL |
| 2 | vertebral anomalies and variable endocrine and T-cell dysfunction | KG + DL |
| 3 | retroperitoneal neoplasm | KG + DL |
| 4 | composite lymphoma | KG + DL |
| 5 | ovarian lymphoma | KG + DL |
| 6 | AIDS-related primary central nervous system lymphoma | KG + DL |
| 7 | nasal cavity lymphoma | KG + DL |
| 8 | progressive transformation of germinal centers | KG + DL |
| 9 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | KG + DL |
| 10 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | KG + DL |
| 11 | mediastinal malignant lymphoma | KG + DL |
| 12 | ureteral lymphoma | KG + DL |
| 13 | breast lymphoma | KG + DL |
| 14 | lymphoid neoplasm | KG + DL |
| 15 | systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood | KG + DL |
| 16 | primary pulmonary lymphoma | KG + DL |
| 17 | methotrexate-associated lymphoproliferative disorders | KG + DL |
| 18 | pulmonary blastoma | KG + DL |
| 19 | hydroa vacciniforme-like lymphoma | KG + DL |
| 20 | well-differentiated fetal adenocarcinoma of the lung | KG + DL |
| 21 | B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma | KG + DL |
| 22 | tracheal lymphoma | KG + DL |
| 23 | lymphoid hemopathy | KG + DL |
| 24 | bladder lymphoma | KG + DL |
| 25 | retroperitoneal lymphoma | KG + DL |
| 26 | small cell lung carcinoma | KG + DL |
| 27 | eye lymphoma | KG + DL |
| 28 | chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 29 | botryoid-type embryonal rhabdomyosarcoma of the vagina | KG + DL |
| 30 | primary effusion lymphoma | KG + DL |
| 31 | parameningeal embryonal rhabdomyosarcoma | KG + DL |
| 32 | MALT lymphoma | KG + DL |
| 33 | embryonal extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 34 | lung lymphoma | KG + DL |
| 35 | B-cell prolymphocytic leukemia | KG + DL |
| 36 | extrahepatic bile duct rhabdomyosarcoma | KG + DL |
| 37 | prostate embryonal rhabdomyosarcoma | KG + DL |
| 38 | small intestinal Burkitt lymphoma | KG + DL |
| 39 | thyroid gland mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 40 | bladder transitional cell carcinoma | KG + DL |
| 41 | Hodgkin’s lymphoma, lymphocytic depletion | KG + DL |
| 42 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | KG + DL |
| 43 | plasma cell neoplasm | KG + DL |
| 44 | small intestinal mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 45 | breast mucosa-associated lymphoid tissue lymphoma | KG + DL |
| 46 | upper aerodigestive tract neoplasm | KG + DL |
| 47 | tonsillar lymphoma | KG + DL |
| 48 | precursor lymphoblastic lymphoma/leukemia | KG + DL |
| 49 | nodular lymphocyte predominant Hodgkin lymphoma | KG + DL |
| 50 | acute lymphoblastic leukemia | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.